Veronica Mollica, MD, continues her discussion on her recent study investigating prognostic factors and clinical outcomes in penile squamous cell carcinoma as well as highlighting the differences in PFS based on the type of chemotherapy regimen administered. Dr. Mollica also explains her thoughts on the potential necessity of continued evaluation of prognostic factors and clinical outcomes for patients with PSCC. ...
Testicular, Penile, and Rare Malignancies
Advertisement
Latest News
Dr. Mollica highlights her recent research investigating prognostic factors and clinical outcomes for patients with PSCC.
The IGCCCG was used to compare the survival probabilities of patients with testicular GCTs with or without teratoma.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
While most STMs are benign, between 13% and 21% are malignant, and distinguishing between them remains a challenge.
Research into the potential benefits of ctDNA for patients with testicular cancer both before and after diagnosis is lacking.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Advertisement
Advertisement
Latest News
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
